Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
27 mars 2023 16h05 HE
|
Harpoon Therapeutics
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million...
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
27 mars 2023 16h02 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers,...
Multiple Myeloma Market to Exhibit a Remarkable Growth of USD 38.94 Billion by 2029, Size, Share, Trends, Key Drivers, Growth and Opportunity Analysis
22 mars 2023 13h30 HE
|
Data Bridge Market Research
HOUSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Multiple Myeloma Market" with 100+ market data tables, pie charts, graphs, and figures...
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
16 mars 2023 03h00 HE
|
Anaveon
BASEL, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study - a...
International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023
23 févr. 2023 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to...
International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event
02 févr. 2023 08h45 HE
|
International Myeloma Foundation
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and...
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
11 déc. 2022 10h00 HE
|
Harpoon Therapeutics
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed...
CURE Media Group announces D.L. Hughley as keynote panel moderator for the 2022 Multiple Myeloma Heroes and Health Equity Heroes awards
05 déc. 2022 13h38 HE
|
CURE Media Group
CRANBURY, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
01 déc. 2022 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE...
CURE Media Group announces 2022 Multiple Myeloma Heroes®
17 nov. 2022 09h00 HE
|
CURE Media Group
CRANBURY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...